微小RNA作为弥漫性大B细胞淋巴瘤潜在的诊断和预后生物标志物：一项系统综述和荟萃分析
MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
作者信息
Khanmohammadi Shaghayegh, Masrour Mahdi, Fallahtafti Parisa, Hasani Fatemeh
机构信息
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Cancer Rep (Hoboken). 2025 Jan;8(1):e70070. doi: 10.1002/cnr2.70070.
BACKGROUND
Recently, microRNAs (miRNAs) have been applied as biomarkers for diffuse large B-cell lymphoma (DLBCL) patients. Early diagnosis and management of DLBCL can improve patient survival and prognosis.
AIMS
This systematic review and meta-analysis aimed to evaluate the diagnostic and prognostic accuracy of miRNA biomarkers in DLBCL patients.
METHODS
We used the keywords "diffuse large B-cell lymphoma" and "microRNA" to search databases for original publications until June 14, 2023. Specificity, sensitivity, and AUC were used to assess diagnostic accuracy, and the prognostic value was assessed using the overall survival (OS) and progression-free survival (PFS) hazard ratio (HR). A subgroup analysis was performed based on the sample type acquired to investigate the heterogeneity.
RESULTS
Thirteen diagnostic and 33 prognostic studies were included from 839 articles. The Reitsma bivariate model estimated a sensitivity of 0.788 (95% CI: 0.733-0.834, p < 0.001), a specificity of 0.727 (95% CI: 0.654-0.790, p < 0.001), and an AUC of 0.824 in. The pooled AUC was 0.7385 (95% CI: 0.6847-0.7923, p < 0.0001). The pooled OS and PFS HRs (> 1) were 2.2847 (95% CI: 1.7248-3.0263, p < 0.0001) and 2.4883 (95% CI: 1.7367-3.5650, p < 0.0001). The pooled OS and PFS HRs (< 1) were 0.4965 (95% CI: 0.3576-0.6894, p < 0.0001) and 2.4883 (95% CI: 1.7367-3.5650, p < 0.0001). MiR-155 diagnostic values had a sensitivity of 0.710 (p > 0.1) and a specificity of 0.725 (p < 0.05), with an AUC of 0.776. miR-21 diagnostic values had an AUC of 0.8468 (p < 0.0001) and OS HR of 2.8938.
CONCLUSION
MicroRNAs could serve as a powerful diagnostic and prognostic tool in DLBCL.
背景
近年来，微小RNA（miRNA）已被用作弥漫性大B细胞淋巴瘤（DLBCL）患者的生物标志物。DLBCL的早期诊断和管理可改善患者的生存率和预后。
目的
本系统评价和荟萃分析旨在评估miRNA生物标志物在DLBCL患者中的诊断和预后准确性。
方法
我们使用关键词“弥漫性大B细胞淋巴瘤”和“微小RNA”检索数据库，以获取截至2023年6月14日的原始出版物。使用特异性、敏感性和曲线下面积（AUC）评估诊断准确性，并使用总生存期（OS）和无进展生存期（PFS）风险比（HR）评估预后价值。根据获取的样本类型进行亚组分析，以研究异质性。
结果
从839篇文章中纳入了13项诊断研究和33项预后研究。Reitsma双变量模型估计敏感性为0.788（95%CI：0.733 - 0.834，p < 0.001），特异性为0.727（95%CI：0.654 - 0.790，p < 0.001），AUC为0.824英寸。合并后的AUC为0.7385（95%CI：0.6847 - 0.7923，p < 0.0001）。合并后的OS和PFS HRs（>1）分别为2.2847（95%CI：1.7248 - 3.0263，p < 0.0001）和2.4883（95%CI：1.7367 - 3.5650，p < 0.0001）。合并后的OS和PFS HRs（<1）分别为0.4965（95%CI：0.3576 - 0.6894，p < 0.0001）和2.4883（95%CI：1.7367 - 3.5650，p < 0.0001）。MiR - 155的诊断值敏感性为0.710（p > 0.1），特异性为0.725（p < 0.05），AUC为0.776。miR - 21的诊断值AUC为0.8468（p < 0.0001），OS HR为2.8938。
结论
微小RNA可作为DLBCL中一种强大的诊断和预后工具。
Zotero 插件